ArticleThe New England journal of medicine2015
Factor XI antisense oligonucleotide for venous thrombosis.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.Journal of thrombosis and haemostasis : JTH · 2022Trial
- Factor XI: structure, function and therapeutic inhibition.Journal of thrombosis and thrombolysis · 2024Review
- Article
- Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis.Journal of thrombosis and haemostasis : JTH · 2022Article
- Antisense technology: an overview and prospectus.Nature reviews. Drug discovery · 2021Review
- Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.Journal of thrombosis and haemostasis : JTH · 2021Article
- Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability.Blood · 2019Article
- Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist.Internal and emergency medicine · 2018Article
- Cell Receptor and Cofactor Interactions of the Contact Activation System and Factor XI.Frontiers in medicine · 2018Review
- mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation.Blood · 2016Article
- Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.Intractable & rare diseases research · 2016Review
- Antisense technology: A review.The Journal of biological chemistryReview
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
25901434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.